

PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	IP Security Agreement Supplement
CONVEYING PARTY DATA	
Name	Execution Date
CaridianBCT Biotechnologies, LLC	01/31/2009
RECEIVING PARTY DATA	
Name:	Citicorp Trustee Company Limited
Street Address:	Citigroup Centre
City:	London
State/Country:	UNITED KINGDOM
Postal Code:	E14 5LB
PROPERTY NUMBERS Total: 24	
Property Type	Number
Patent Number:	7186543
Patent Number:	7220747
Patent Number:	7183045
Patent Number:	7438679
Application Number:	10377524
Application Number:	10648536
Application Number:	10904361
Application Number:	11079894
Application Number:	11268077
Application Number:	11428669
Application Number:	11469186
Application Number:	11607737
Application Number:	11624487
Application Number:	11626607
Application Number:	11626692

CH \$960.00 7186543

500865652

PATENT
REEL: 022714 FRAME: 0560

Application Number:	11688694
Application Number:	11840759
Application Number:	11875334
Application Number:	11932629
Application Number:	12032963
Application Number:	12182280
Application Number:	12190854
Application Number:	11154503
Application Number:	61147569

CORRESPONDENCE DATA

Fax Number: (202)408-3141

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 202-408-3121 x2348

Email: jpaterso@cscinfo.com

Correspondent Name: Corporation Service Company

Address Line 1: 1090 Vermont Avenue NW, Suite 430

Address Line 2: Attn: Jean Paterson

Address Line 4: Washington, DISTRICT OF COLUMBIA 20005

ATTORNEY DOCKET NUMBER:	011812-015
-------------------------	------------

NAME OF SUBMITTER:	Jean Paterson
--------------------	---------------

Total Attachments: 8

source=5-20-09 CaridianBCT Biotechnologies-PT#page1.tif
source=5-20-09 CaridianBCT Biotechnologies-PT#page2.tif
source=5-20-09 CaridianBCT Biotechnologies-PT#page3.tif
source=5-20-09 CaridianBCT Biotechnologies-PT#page4.tif
source=5-20-09 CaridianBCT Biotechnologies-PT#page5.tif
source=5-20-09 CaridianBCT Biotechnologies-PT#page6.tif
source=5-20-09 CaridianBCT Biotechnologies-PT#page7.tif
source=5-20-09 CaridianBCT Biotechnologies-PT#page8.tif

Intellectual Property Security Agreement Supplement

This **INTELLECTUAL PROPERTY SECURITY AGREEMENT SUPPLEMENT** (this "IP Security Agreement Supplement") dated as of January 31, 2009 is made by CaridianBCT Biotechnologies, LLC (the "Grantor") in favor of Citicorp Trustee Company Limited, as Security Agent (the "Security Agent") for the Secured Parties (as defined below).

WHEREAS, Gambro Holding AB (formerly Indap AB; now succeeded as Gambro AB) (the "Parent"), a company organized under the laws of Sweden, and certain of its Subsidiaries (including the Grantor) have entered into a Senior Facilities Agreement dated 5 June 2006, as amended by an amendment agreement dated 7 June 2006, as amended and restated pursuant to amendment and restatement agreements dated 18 July 2006, 9 November 2006 and 20 March 2007 and as amended pursuant to an amendment letter dated 24 July 2007 (said Agreement, as the same may further be amended, amended and restated, supplemented or otherwise modified from time to time, being the "Senior Facilities Agreement") with Citibank International plc as agent (the "Senior Agent"), the Security Agent, Citigroup Global Markets Limited and Morgan Stanley Bank International Limited as mandated lead arrangers (the "Arrangers"), the Original Lenders (as defined therein) and others.

WHEREAS, the Parent has entered into a Mezzanine Facility Agreement dated 5 June 2006, as amended by amendment agreements dated 7 June 2006 and 11 December 2006, as amended and restated pursuant to amendment and restatement agreements dated 9 November 2006 and 20 March 2007 and as amended pursuant to an amendment letter dated 24 July 2007 (said Agreement, as the same may further be amended, amended and restated, supplemented or otherwise modified from time to time, being the "Mezzanine Facility Agreement" and, together with the Senior Facilities Agreement, the "Facilities Agreements") with the Arrangers, Citibank International plc as agent (the "Mezzanine Agent"), the Original Lenders (as defined therein) and the Security Agent.

WHEREAS, the Parent has entered into an Intercreditor Agreement dated 5 June 2006 and as amended and restated pursuant to an amendment and restatement agreement dated 9 November 2006 (said Agreement, as the same may further be amended, amended and restated, supplemented or otherwise modified from time to time, being the "Intercreditor Agreement"), with the banks and financial institutions listed therein as the Original Senior Lenders and the Original Mezzanine Lenders, the Senior Agent, the Mezzanine Agent, the Security Agent and others.

WHEREAS, pursuant to the Facilities Agreement, the Grantor and certain other Persons have executed and delivered that certain Security Agreement dated as of November 17, 2006 made by the Grantor and such other persons to the Security Agent (as amended, amended and restated, supplemented or otherwise modified from time to time, the "Security Agreement"). To create a short form version of the Security Agreement covering certain intellectual property of the Grantor and such other Persons for recording with the U.S. Patent and Trademark Office, the United States Copyright Office and other governmental authorities, the Grantor and such other persons have executed and delivered that certain Intellectual Property Security Agreement made by the Grantor and such other Persons to the Security Agent dated as of November 17, 2006 (as the same may be further amended, amended and restated,

supplemented or otherwise modified from time to time, the "IP Security Agreement"). Terms defined in the Security Agreement and not otherwise defined herein are used herein as defined in the Security Agreement.

WHEREAS, under the terms of the Security Agreement and the IP Security Agreement, the Grantor has granted a security interest in the Additional Collateral (as defined in Section 1 below) of such Grantor to the Security Agent for the rateable benefit of the Secured Parties and has agreed as a condition thereof to execute this IP Security Agreement Supplement for recording with the U.S. Patent and Trademark Office and other governmental authorities.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor agrees as follows:

1. Confirmation of Grant of Security

The Grantor hereby acknowledges and confirms the grant of a security interest to the Security Agent for the rateable benefit of the Secured Parties under the Security Agreement and the IP Security Agreement in and to all of the Grantor's right, title and interest in and to the following (the "Additional Collateral"):

- 1.1 all material United States, patents, patent applications, and patent licenses set forth in Schedule A hereto, together with all reissues, divisions, continuations, continuations-in-part, extensions and reexaminations thereof, and all rights therein provided by international treaties or conventions (the "Patents");
- 1.2 all material United States trademark and service mark registrations, applications, and licenses set forth in Schedule B hereto (the "Trademarks");
- 1.3 any and all claims for damages for past, present and future infringement, misappropriation or breach with respect to the Patents and Trademarks, with the right, but not the obligation, to sue for and collect, or otherwise recover, such damages; and
- 1.4 any and all proceeds of the foregoing.

2. Supplement to Security Agreement and IP Security Agreement

Schedule 5 to the Security Agreement and Schedules A and B to the IP Security Agreement are each, effective as of the date hereof, hereby supplemented to add to such Schedules the Additional Collateral.

3. Recordation

The Grantor authorizes and requests that the Commissioner of Patents and Trademarks and any other applicable government officer to record this IP Security Agreement Supplement.

4. Governing Law

This IP Security Agreement Supplement shall be governed by, and construed in accordance with, the laws of the State of New York.

4. Governing Law

This IP Security Agreement Supplement shall be governed by, and construed in accordance with, the laws of the State of New York.

IN WITNESS WHEREOF, the Grantor has caused this IP Security Agreement Supplement to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

CARDIANBCT BIOTECHNOLOGIES,
LLC (formerly known as Navigant
Biotechnologies LLC)

By



Name: Katherine L MacWilliams

Title: Treasurer & CFO

SCHEDULE A
PATENTS AND TRADEMARKS

CaridianBCT Biotechnologies, LLC

PATENTS

(as of January 15, 2009)

Country	Patent Number	Owner	Grant Date	Expires	Title
US	7186543	CaridianBCT Biotechnologies, LLC	06-Mar-2007	22-Dec-2023	Preparation of Vaccines Using Photosensitizer and Light
US	7220747	CaridianBCT Biotechnologies, LLC	22-May-2007	28-Feb-2024	Method for Preventing Damage to or Rejuvenating a Cellular Blood Component Using Mitochondrial Enhancer
US	7183045	CaridianBCT Biotechnologies, LLC	27-Feb-2007	29-Jul-2024	Removal of Adenine During a Pathogen Reduction Process in Whole Blood or Red Blood Cells by Dilution
US	7438679	CaridianBCT Biotechnologies, LLC	21-Oct-2008	05-Jun-2026	Apparatus and Method for Separating Volumes of a Composite Liquid with a Balancing Assembly

PATENT APPLICATIONS

(as of February 11, 2009)

COUNTRY	CURRENT RECORDED OWNER	APPLICATION NUMBER	PUBLICATION NUMBER	TITLE
US	CARIDIANBCT BIOTECHNOLOGIES, LLC	10/377524	2003-0215784	Additive Solutions Comprising Riboflavin (formerly titled Method and Apparatus for Inactivation of Biological Contaminants Using Photosensitizers)
US	CARIDIANBCT BIOTECHNOLOGIES, LLC	10/648536	2004-0081956	Induction of and Maintenance of Nucleic Acid Damage in Pathogens Using Riboflavin and Light
US	CARIDIANBCT BIOTECHNOLOGIES, LLC	10/904361	2005-0112021	Reduction of Contaminants in Blood and Blood Products Using Photosensitizers and Peak Wavelengths of Light
US	CARIDIANBCT BIOTECHNOLOGIES, LLC	11/079894	2005-0202395	Methods For Uniformly Treating Biological Samples With Electromagnetic Radiation
US	CARIDIANBCT BIOTECHNOLOGIES, LLC	11/268077	2007-0102858	Clamps and Methods for Displacing Fluid from Portions of Fluid Containers
US	CARIDIANBCT BIOTECHNOLOGIES, LLC	11/428669	2007-0009377	Methods for Reducing Pathogens in Biological Samples
US	CARIDIANBCT BIOTECHNOLOGIES, LLC	11/469186	2007-0098697	Preventing Transfusion Related Complications in a Recipient of a Blood Transfusion
US	CARIDIANBCT BIOTECHNOLOGIES, LLC	11/607737	2007-0099170	Method for Treatment and Storage of Blood and Blood Products Using Endogenous Alloxazines and Acetate
US	CARIDIANBCT BIOTECHNOLOGIES, LLC	11/624487	2007-0148630	Removal of Adenine During A Pathogen Reduction Process in Whole Blood or Red Blood Cells by Dilution
US	CARIDIANBCT BIOTECHNOLOGIES, LLC	11/626607	2007-0212379	Preparation of Vaccines Using Photosensitizer and Light
US	CARIDIANBCT BIOTECHNOLOGIES, LLC	11/626692	2007-0178437	Methods and Compositions for the Production of High Concentration Alloxazine Solutions
US	CARIDIANBCT BIOTECHNOLOGIES, LLC	11/688694	2008-0234622	Methods and Systems for Preparing Blood Products
US	CARIDIANBCT BIOTECHNOLOGIES, LLC	11/840759	2008-0176208	Reduction of Contaminants in Blood and Blood Products Using Photosensitizers and Peak Wavelengths of Light
US	CARIDIANBCT BIOTECHNOLOGIES, LLC	11/875334	2008-0096750	Methods for Washing a Red Blood Cell Component and for Removing Prions Therefrom
US	CARIDIANBCT BIOTECHNOLOGIES, LLC	11/932629	2008-0107636	Induction of and Maintenance of Nucleic Acid Damage in Pathogens Using Riboflavin and Light
	CARIDIANBCT	12/032963	2009-0010806	Apparatus for Photo Reduction of

COUNTRY	CURRENT RECORDED OWNER	APPLICATION NUMBER	PUBLICATION NUMBER	TITLE
US	BIOTECHNOLOGIES, LLC			Contaminants in Blood and Blood Products with Calibration Means
US	CARIDIANBCT BIOTECHNOLOGIES, LLC	12/182280	2008-0299538	Pathogen Inactivation of Whole Blood
US	CARIDIANBCT BIOTECHNOLOGIES, LLC	12/190854	2009-0023130	Prevention of Transfusion Related Acute Lung Injury Using Riboflavin and Light
US	CARIDIANBCT BIOTECHNOLOGIES, LLC & OHIO STATE UNIVERSITY FOUNDATION	11/154503	2005-0282143	Use of Visible Light at Wavelengths of 500 nm and Higher to Pathogen Reduce Blood and Blood Components

PATENT PROVISIONAL APPLICATIONS

(as of February 11, 2009)

COUNTRY	CURRENT OWNER	APPLICATION NUMBER	APPLICATION DATE	EXPIRATION DATE	TITLE
US	CARDIANBCT BIOTECHNOLOGIES, LLC	61/147569	1/27/2009	1/27/2010	Prevention of Transfusion-Related Immunomodulation (TRIM) in Recipients of Blood Transfusions